Federal Rescheduling of Medical Cannabis Creates Uncertainty for States
The U.S. Department of Justice in April downgraded the drug classification for medical cannabis from Schedule I to Schedule III, acknowledging an accepted healthcare use for the substance. The change allows medical marijuana businesses to claim some federal tax benefits and permits new research at state universities. However, recreational marijuana remains a Schedule I drug under federal policy, even though 24 states and the District of Columbia allow recreational cannabis. The U.S. Drug Enforcement Administration is scheduled to hold its first hearing at the end of June on the possible de-scheduling of marijuana broadly, which would include recreational use. State cannabis regulators in Oklahoma, Vermont, Washington, and others are waiting for further federal guidance before determining new compliance requirements. Some industry leaders say the rescheduling could ease tax constraints and shift investor attitudes, while others note the change also creates confusion due to overlapping federal and state rules.
What’s reported
The U.S. Department of Justice reclassified medical marijuana from Schedule I to Schedule III in April 2026.
Recreational marijuana remains a Schedule I drug; 24 states and D.C. allow recreational cannabis.
The DEA will hold its first hearing on possible de-scheduling of marijuana broadly at the end of June.
States with existing medical or recreational programs are expected to see little immediate change until federal regulations are clarified.
The rescheduling allows medical cannabis licensees to register with the DEA, but state laws have not changed.
California proposed emergency regulations in mid-May to allow businesses with both medical and recreational licenses to obtain separate licenses.
The U.S. Department of Transportation stated in December that drug testing and licensing standards will not change; TSA rules still prohibit carrying marijuana on flights.
Some experts say rescheduling reduces barriers to studying cannabis medical use, safety, and health effects.
The attorneys general of Indiana, Louisiana, and Nebraska filed a petition for review in the U.S. Court of Appeals arguing the rescheduling order violates federal administrative law.
Conflicting accounts
The Oklahoma Bureau of Narcotics and Dangerous Drugs Control sent a letter encouraging medical cannabis businesses to register with the DEA and warning of possible sanctions. However, the Oklahoma Medical Marijuana Authority said the letter came as a surprise and it remains unclear whether federal officials intend to require DEA registration. The source article does not resolve this conflict.
Open questions
Whether businesses will be required to register with the DEA, qualify for federal tax relief, or face new compliance requirements.
Whether states may need to revise their own cannabis laws.
How federal agencies like the IRS and Treasury will issue guidance on rescheduling.
Whether future court challenges or a change in administration could reverse the rescheduling.
Misconceptions
Some public health and addiction experts caution that the federal shift should not be interpreted as cannabis being risk-free, citing concerns about cannabis use disorders, dependency, and mental health effects. Opponents argue the change is driven by political and economic pressure from the cannabis industry, not by evolving science. The source does not indicate these are widespread misconceptions but presents them as expert opinions.
Key figures
Katharine Neill Harris, drug policy fellow at Rice University’s Baker Institute for Public Policy
Heather Trela, director of operations and fellow at the Rockefeller Institute of Government
James Pepper, chair of the Vermont Cannabis Control Board
Lauren Niehaus, executive director of government relations at Trulieve Cannabis Corp.
Ryan Hunter, chief revenue officer of Spherex Labs (Colorado)
Chad Johnson, assistant professor of pharmaceutical sciences at University of Maryland School of Pharmacy
Dr. Alta DeRoo, chief medical officer of Hazelden Betty Ford Foundation
Kevin Sabet, president and CEO of Smart Approaches to Marijuana
Sources: stateline.org
